Truebinding, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.truebinding.com
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- TrueBinding, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT06773962
- Locations
- 🇺🇸
NYU Langone Health, Patchogue, New York, United States
🇺🇸Parkinson's Research Centers of America - Orange County, Aliso Viejo, California, United States
🇺🇸Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
TB006 Expanded Access (EA) Compassionate Use
- Conditions
- Alzheimer Disease
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- TrueBinding, Inc.
- Registration Number
- NCT05959239
A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- TrueBinding, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT05476783
- Locations
- 🇺🇸
Clinical Trial Site, Fairfax, Virginia, United States
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- TrueBinding, Inc.
- Registration Number
- NCT05156827
Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- TrueBinding, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT05074498
- Locations
- 🇺🇸
Clinical Trial Site, Fairfax, Virginia, United States
🇺🇸Clinical Trial Site #1, Maitland, Florida, United States
- Prev
- 1
- 2
- Next
News
Investigational Monoclonal Antibody TB006 Shows Promise in Reversing Alzheimer's Disease Through Galectin-3 Targeting
TB006, an investigational monoclonal antibody developed by TrueBinding, Inc., targets galectin-3 protein and has shown potential to reverse Alzheimer's disease in studies.